Todas las noticias

Reverse split of Spineway shares

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that it has decided to carry out a reverse split of its share capital on the basis of 1 new share for 2,000 old shares.

Comunicados de prensa

International rollout of the VEOS implant range

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces the accelerated rollout of its range of VEOS implants for intervertebral fixation by posterior approach into new markets.

Comunicados de prensa

Minutes of the General Meeting of November 10, 2023

An Extraordinary General Mee1ng of Spineway shareholders was held on first no1ce on Friday, November 10, 2023 at 9:30 a.m. at the company’s registered office, 7 allée Moulin Berger in Ecully (69)

Comunicados de prensa

Appointment of Sandrine Carle as Deputy Chief Executive Officer

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces the appointment of Sandrine Carle as Deputy Chief Executive Officer. Ms. Carle joined Spineway in July 2022, at the time of the acquisition of Spine Innovations, where she was CEO. She was instrumental in the successful integration of Spine Innovations into the Spineway Group.

Comunicados de prensa

VEOS system well perceived at the NASS 2023 conference in the United States / Sales growth in France

Spineway Group, specialists in innovative implants for the treatment of severe spinal pathologies, is pleased to announce that its VEOS posterior spinal fixation system received an excellent response from the spine implant industry at the North American Spine Society (NASS) Congress in Los Angeles last October1.

Comunicados de prensa

Spineway obtains 510(k) clearance from the FDA for its VEOS spinal fixation system

Spineway Group, a specialist in innovative implants for the treatment of severe spinal conditions, is pleased to announce the recent 510(k) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System.

Comunicados de prensa

9-month revenue up 40% at €7.5 million

Spineway recorded revenue of €2.1 million in the third quarter of 2023, taking the 9-month total to €7.5 million, a 40% increase compared with 2022. Revenue growth over the first 9 months was driven mainly by sales by Spine Innovations, consolidated in July 2022. As announced, third-quarter revenue was automatically impacted by a less favorable impact from change in scope.

Comunicados de prensa

H1 2023 results

The Board of Directors of Spineway, meeting on September 18, 2023, under the chairmanship of Stéphane Le Roux, approved the financial statements for the six months to June 30, 2023.

Comunicados de prensa

Spineway organizes an international masterclass with expert spine surgeons

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its Spineway Academy department, with the support of GECO1(Groupe d’études de la Chirurgie Osseuse – Bone Surgery Study Group) and its SAC (Spine Arthroplasty Community) working group, has organized a masterclass on cervical and lumbar disc prostheses with French and international surgeons. This event was held on September 9 in Behoust (France) and focused on total disc replacement using prostheses.

Comunicados de prensa
CARGANDO